On March 10, the Department of Justice (DOJ) moved to drop a lawsuit filed on behalf of the Federal Trade Commission (FTC) against Xlear, ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

Xlear says the move calls FTC’s authority to require clinical studies for non-pharmaceutical health products into question.

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...

According to a research, two Australian respiratory scientists are looking to develop a nasal spray for Covid-19 vaccination. Professor Daniela Traini from Macquarie University and Professor Pall ...

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal designed to fuel the preclinical company’s R&D.

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Emergent BioSolutions (EBS) and Rocketvax announced entry into an agreement for Emergent’s strategic financial investment into Swiss Rockets, ...

Background: In October 2021, the FTC filed a lawsuit against Xlear and Jones alleging that the company’s statements that Xlear nasal spray could serve an effective, additional layer of protection ...